Healthcare · NIFTY 500
Emcure Pharmaceuticals Limited
₹2,314.40 +82.00 (+3.67%) Updated 12 Nov, 8:19 pm IST
Today
- Open
- ₹2,260.00
- Prev close
- ₹2,232.40
- Day high
- ₹2,344.40
- Day low
- ₹2,243.60
- Volume
- 9.65 L
- Value traded
- ₹222.17 Cr
- Upper circuit
- ₹2,455.60
- Lower circuit
- ₹2,009.20
- 52W high
- ₹2,314.40
- 52W low
- ₹1,306.50
- 1 month
- +19.51%
- 6 months
- +31.87%
Ratios
Key numbers
Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.
Quarterly results
Results for each quarter
Last 10 quarters, consolidated, ₹ crore. Hover a bar to see the number.
Revenue and net profit
Revenue · QoQ (vs last quarter)
Revenue · YoY (vs a year ago)
Net profit · QoQ (vs last quarter)
Net profit · YoY (vs a year ago)
EPS (₹) · YoY (vs a year ago)
| ₹ Cr | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,815 | 2,002 | 1,963 | 2,116 | 2,101 | 2,270 | 2,363 | 2,470 | 2,580 | 2,820 |
| Other income | 23.4 | 35.7 | 3.9 | 4.5 | 3.7 | 3.1 | 1.9 | 4.0 | 2.1 | 3.3 |
| Total income | 1,839 | 2,038 | 1,967 | 2,121 | 2,104 | 2,273 | 2,365 | 2,474 | 2,583 | 2,824 |
| Raw material | 332 | 391 | 400 | 404 | 433 | 420 | 421 | 419 | 481 | 642 |
| Purchases | 380 | 502 | 429 | 572 | 550 | 625 | 560 | 661 | 555 | 625 |
| Employee cost | 350 | 356 | 367 | 373 | 393 | 385 | 387 | 387 | 409 | 435 |
| Other expenses | 445 | 477 | 458 | 448 | 488 | 520 | 521 | 600 | 565 | 656 |
| Total expenses | 1,631 | 1,764 | 1,737 | 1,850 | 1,810 | 1,932 | 2,013 | 2,143 | 2,189 | 2,378 |
| Operating profit | 336 | 381 | 355 | 392 | 413 | 475 | 455 | 490 | 532 | 588 |
| OPM % | 18.5% | 19.0% | 18.1% | 18.5% | 19.7% | 20.9% | 19.2% | 19.8% | 20.6% | 20.8% |
| Finance cost | 58.8 | 46.2 | 31.8 | 39.0 | 26.8 | 32.5 | 38.0 | 46.4 | 31.5 | 35.6 |
| Depreciation | 93.6 | 96.9 | 96.8 | 96.8 | 99.5 | 105 | 105 | 106 | 110 | 110 |
| Exceptional items | — | — | — | -10.4 | -3.5 | — | -38.2 | 10.3 | — | — |
| Profit before tax | 207 | 273 | 230 | 261 | 291 | 341 | 314 | 341 | 394 | 446 |
| Tax | 54.8 | 71.9 | 73.8 | 63.4 | 76.0 | 90.0 | 82.4 | 97.4 | 101 | 121 |
| Net profit | 153 | 202 | 156 | 197 | 215 | 251 | 231 | 244 | 292 | 325 |
| Profit to shareholders | 144 | 195 | 154 | 189 | 207 | 243 | 231 | 243 | 294 | 326 |
| EPS (₹) | 7.95 | 10.33 | 8.12 | 9.97 | 10.92 | 12.85 | 12.16 | 12.84 | 15.50 | 17.14 |
Profit & loss
Results for each year
2 financial years (April to March), consolidated, ₹ crore.
Sales, operating profit and net profit
Revenue · YoY (vs a year ago)
Net profit · YoY (vs a year ago)
| ₹ Cr | FY25 | FY26 |
|---|---|---|
| Revenue | 7,896 | 9,204 |
| Other income | 67.3 | 12.7 |
| Total expenses | 6,982 | 7,898 |
| Employee cost | 1,446 | 1,552 |
| Operating profit | 1,464 | 1,833 |
| OPM % | 18.5% | 19.9% |
| Finance cost | 176 | 144 |
| Depreciation | 384 | 415 |
| Profit before tax | 971 | 1,287 |
| Tax | 264 | 346 |
| Tax rate % | 27.2% | 26.9% |
| Net profit | 707 | 941 |
| Profit to shareholders | 681 | 924 |
| Net margin % | 8.6% | 10.0% |
| EPS (₹) | 36.43 | 48.77 |
Balance sheet
Assets and debt
At each year end (and the latest half year), ₹ crore.
Equity, debt and assets
Shareholders' equity · YoY (vs a year ago)
| ₹ Cr | Mar 25 | Mar 26 | Sep 26 |
|---|---|---|---|
| Shareholders' equity | 4,446 | 4,950 | 5,344 |
| Long-term borrowings | 190 | 252 | 537 |
| Short-term borrowings | 542 | 952 | 930 |
| Total borrowings | 732 | 1,204 | 1,467 |
| Current liabilities | 2,668 | 3,912 | 3,839 |
| Fixed assets (PPE) | 1,954 | 1,960 | 1,986 |
| Inventories | 1,932 | 2,398 | 2,505 |
| Trade receivables | 2,002 | 2,563 | 2,731 |
| Cash & equivalents | 156 | 137 | 137 |
| Current assets | 4,650 | 5,709 | 6,143 |
| Total assets | 8,233 | 9,612 | 10,164 |
| Debt / equity | 0.16 | 0.24 | 0.27 |
Cash flow
Cash coming in and going out
For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.
Operating, investing and financing cash
Operations · YoY (vs a year ago)
| ₹ Cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 852 | 944 |
| Cash from investing | -94.0 | -1,193 |
| Cash from financing | -814 | 343 |
| Spent on fixed assets | -222 | -361 |
| Free cash flow | 630 | 583 |
| Net cash flow | -56.3 | 93.9 |
Shareholding
Who holds the shares
Promoter and public holding at each quarter end, as filed with NSE.
Holding over time
Latest (30 Sep 2026)
- Promoter & group
- 77.82%
- Public (FIIs, mutual funds, retail…)
- 22.18%
- Promoter change, last quarter
- -0.01 pts
Dividends & news
Latest dividends and announcements
Dividends & corporate actions
- Dividend - Rs 3.60 Per Share
- Dividend - Rs 3 Per Share
Board meetings
- EMCURE PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to inter-alia consider and approve the Unaudit…
- the Unaudited Financial Results for the quarter and half year ended September 30, 2026
- EMCURE PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 06-Aug-2026 to inter-alia consider and approve the Unaudit…
- the financial results for the period ended Jun 30, 2026
- the Yearly Audited Financial results of the Company for the period ended March 2026 and Dividend.
Filings with NSE
- Analysts/Institutional Investor Meet/Con. Call Updates
- Analysts/Institutional Investor Meet/Con. Call Updates
- Copy of Newspaper Publication
- Analysts/Institutional Investor Meet/Con. Call Updates
- Investor Presentation
- Outcome of Board Meeting
- Analysts/Institutional Investor Meet/Con. Call Updates
Latest news
Emcure Pharma surges 10%, stock hits new high on strong outlookBusiness Standard · 4 Nov, 10:08 amEmcure Pharma shares gain 3% as Motilal Oswal initiates coverage with Buy; sees 23% upsideMoneycontrol.com · 20 Jul, 12:30 pmEmcure Pharma Shares May Rally Up To 33%, Says MOFSL On Strong Growth Outlook; Check Target PriceNDTV Profit · 22 Oct, 12:30 pmEmcure Pharma Q1 results: Profit jumps 42% YoY to ₹294 crore, revenue climbs 23%; check key numbersUpstox · 6 Aug, 12:30 pmEmcure Pharmaceuticals (NSEI:EMCURE) Stock Forecast & Analyst PredictionsSimply Wall St · 3 Nov, 1:30 pmEmcure Pharmaceuticals Share Price: Price Fall and ValuationUnivest · 19 Oct, 12:30 pmEmcure Pharmaceuticals Share Price Jumps 4% on Monday; Here's WhyDalal Street Investment Journal · 20 Jul, 12:30 pmNifty 500: Emcure hits record high on strong Q2; MCX slips 5% despite doubling profit at market openCNBC TV18 · 4 Nov, 1:30 pmAbout
About Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited (Emcure) is an Indian multinational pharmaceutical company, headquartered in Pune. Emcure's product portfolio includes tablets, capsules (both softgel capsules and hard-gel capsules) and injectables. The company produces gynaecology, cardiovascular, oncology and blood therapeutic drugs, HIV antivirals and other anti-infectives, and vitamins and minerals.
From Wikipedia (CC BY-SA 4.0).
Company details
- Company name
- Emcure Pharmaceuticals Limited
- NSE symbol
- EMCURE
- BSE scrip code
- 544210
- ISIN
- INE168P01015
- Listed on
- NSE, BSE
- Series
- EQ (normal equity)
- Listed on NSE since
- 10 Jul 2024
- Face value
- ₹10 per share
- Market lot
- 1 share
- Shares issued
- 18.97 crore
- Index
- NIFTY 500
- Sector (NSE)
- Healthcare
- Industry
- Pharmaceuticals: Major
- Managing director / CEO
- Satish Mehta
- Chair
- Satish Mehta
- Headquarters
- Pune, Maharashtra, India
- Registered address
- Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India
- Founded
- 1981
- Employees
- 6,914
- Financial year
- April to March
- Results basis
- Consolidated
- Website
- emcure.com
Peers
Other Healthcare stocks
-
DIVISLABDivi's Laboratories
₹11,485.00
+1.04%
-
ALKEMAlkem Laboratories
₹5,302.00
-2.68%
-
GRANULESGranules India
₹840.50
+5.16%
-
SUNPHARMASun Pharmaceutical Industries
₹1,885.00
-0.91%
-
LAURUSLABSLaurus Labs
₹2,400.00
-1.19%
-
AUROPHARMAAurobindo Pharma
₹1,807.20
-1.11%
-
ACUTAASAcutaas Chemicals
₹3,996.10
+2.02%
-
APOLLOHOSPApollo Hospitals Enterprise
₹8,515.00
-1.03%
Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.